Synchron Secures $200 Million to Advance Stentrode Platform Commercialisation
Synchron has raised $200 million in a Series D funding round to accelerate the commercial deployment of its Stentrode brain-computer interface (BCI) platform and develop next-generation interfaces.
Investment Round and New Stakeholders
- Double Point Ventures led the investment round.
- Existing investors include ARCH Ventures, Bezos Expeditions, Khosla Ventures, METIS, and NTI.
- New participants in this round are the Australian National Reconstruction Fund (NRF), Qatar Investment Authority (QIA), T.Rx Capital, K5 Global, IQT, and Protocol Labs.
Use of Funds
The funding will be directed towards speeding up critical clinical studies and expanding Synchron’s multidisciplinary team.
CEO Statement
“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis. This funding brings us closer to commercialising the Stentrode BCI platform while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.” — Tom Oxley, Founder and CEO of Synchron
Synchron aims to make significant advances in brain-computer interfaces, pushing the boundaries of technology for people with paralysis.
Summary: Synchron’s $200 million funding round will drive rapid commercialisation and innovation of its pioneering non-surgical Stentrode brain-computer interface, expanding access for people with paralysis.